Next Time Around, I'd Like to Be a Pharmaceutical Company
According to James Surowiecki in this week's New Yorker, the miracle drug Sovaldi will cure hepatitis C, but a single dose costs one thousand dollars, and the full treatment costs eighty grand . . . and your average hepatitis C patient makes 23,000 dollars a year, and 3.2 million Americans have hepatitis C . . . and because the people taking the drugs aren't really paying much of the cost, and insurers are obligated to cover a drug that doctors deem necessary (but insurers have "virtually zero" ability to negotiate price when a drug has no equivalent) a very strange economy has been created (and by very strange, I mean that taxpayers are going to foot the bill for our half-assed hybrid sort-of-subsidized health care situation . . . although, to play devil's advocate, perhaps eighty grand is a bargain, if it means you won't have to treat a person for a lifetime of complications for hepatitis C).